IP Library Granted Patent US 8,580,762
Granted Patent B2
US 8,580,762 · App. 13/310,157 · Granted Nov 12, 2013

Substituted purine and 7-deazapurine compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,762
App. No.
13/310,157
Granted
Nov 12, 2013
Kind
B2
Abstract

The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Claims (7)

1. A compound selected from

and pharmaceutically acceptable salts thereof.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. A compound

4. A pharmaceutically acceptable salt of

5. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2012
From: OLHAVA, EDWARD J.; CHESWORTH, RICHARD; KUNTZ, KEVIN W.; RICHON, VICTORIA M.; POLLOCK, ROY M.; DAIGLE, SCOTT R.
To: EPIZYME, INC.
Reel/Frame 027601/0080 →